- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06154512
Reálná, multicentrická, prospektivní, observační studie pro PNH v Číně (ReWoPNH)
Reálná, multicentrická, prospektivní, observační studie paroxysmální noční hemoglobinurie (PNH) v Číně
As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.
Přehled studie
Postavení
Podmínky
Detailní popis
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.
PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.
Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Hangzhou, Čína
- Research Site
-
-
Anhui
-
Hefei, Anhui, Čína, 230002
- Research Site
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100000
- Research Site
-
Beijing, Beijing Municipality, Čína, 100044
- Research Site
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510080
- Research Site
-
Guangzhou, Guangdong, Čína, 510180
- Research Site
-
Guangzhou, Guangdong, Čína, 510515
- Research Site
-
-
Guangxi
-
Nanning, Guangxi, Čína, 530021
- Research Site
-
-
Guizhou
-
Guiyang, Guizhou, Čína, 550004
- Research Site
-
-
Hebei
-
Shijiazhuang, Hebei, Čína, 050000
- Research Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, Čína, 150001
- Research Site
-
-
Henan
-
Zhengzhou, Henan, Čína, 450003
- Research Site
-
Zhengzhou, Henan, Čína, 450052
- Research Site
-
Zhengzhou, Henan, Čína, 463599
- Research Site
-
-
Hubei
-
Wuhan, Hubei, Čína, 430030
- Research Site
-
Wuhan, Hubei, Čína, 430000
- Research Site
-
-
Hunan
-
Changsha, Hunan, Čína, 410008
- Research Site
-
Changsha, Hunan, Čína, 410005
- Research Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210029
- Research Site
-
Nantong, Jiangsu, Čína, 226001
- Research Site
-
Xuzhou, Jiangsu, Čína, 221002
- Research Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Čína, 330006
- Research Site
-
Nanchang, Jiangxi, Čína, 330008
- Research Site
-
-
Jilin
-
Changchun, Jilin, Čína, 130021
- Research Site
-
-
Liaoning
-
Shenyang, Liaoning, Čína, 110001
- Research Site
-
-
Shandong
-
Jinan, Shandong, Čína, 250000
- Research Site
-
Qingdao, Shandong, Čína, 266000
- Research Site
-
Zibo, Shandong, Čína, 255090
- Research Site
-
-
Shangdong
-
Linyi, Shangdong, Čína, 276034
- Research Site
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína, 200040
- Research Site
-
Shanghai, Shanghai Municipality, Čína, 200336
- Research Site
-
-
Shanxi
-
Taiyuan, Shanxi, Čína, 030000
- Research Site
-
Xi’an, Shanxi, Čína, 710061
- Research Site
-
Xi’an, Shanxi, Čína, 710068
- Research Site
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610041
- Research Site
-
Chengdu, Sichuan, Čína, 610072
- Research Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Čína, 300020
- Research Site
-
Tianjin, Tianjin Municipality, Čína, 300052
- Research Site
-
Tianjin, Tianjin Municipality, Čína, 300190
- Research Site
-
-
Yunnan
-
Kunming, Yunnan, Čína, 650034
- Research Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Study Population:
Number of patients (estimate): 1000; Inclusion Criteria
- Patients of any age;
- Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
- Patient or patient's family must be willing and able to give written informed consent.
Exclusion Criteria
- Current or previous treatment with a non-eculizumab complement inhibitor;
- Patients in other PNH clinical trials.
- Unable to give written informed consent.
Popis
Inclusion Criteria
- Patients of any age;
- Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
- Patient or patient's family must be willing and able to give written informed consent.
Exclusion Criteria
- Current or previous treatment with a non-eculizumab complement inhibitor;
- Patients in other PNH clinical trials.
- Unable to give written informed consent.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Časové okno: 12 months
|
To characterize the progression of PNH |
12 months
|
|
Number and percentage of patients with thrombosis within follow-up
Časové okno: 12 months
|
To characterize the progression of PNH |
12 months
|
|
average number of units of packed RBCs transfused per month, of all patients
Časové okno: 12 months
|
To characterize the progression of PNH |
12 months
|
|
Number and percentage of patients with renal failure within follow-up
Časové okno: 12 months
|
To characterize the progression of PNH |
12 months
|
|
Number and percentage of patients with pulmonary hypertension within follow-up
Časové okno: 12 months
|
To characterize the progression of PNH |
12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number and percentage of patients with each symptom of interest within follow-up
Časové okno: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Demographics at baseline of all patients
Časové okno: baseline
|
To describe clinical characteristics of patients with PNH in China |
baseline
|
|
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Časové okno: 12 months
|
To describe the treatment pattern of PNH in China |
12 months
|
|
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Časové okno: 12 months
|
To describe the safety of Eculizumab treatment via Serious Adverse Events |
12 months
|
|
Standard descriptive statistics of pregnancy status
Časové okno: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Standard descriptive statistics of lactation status
Časové okno: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Standard descriptive statistics of PNH classification
Časové okno: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Standard descriptive statistics of flow cytometry results
Časové okno: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Časové okno: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Časové okno: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
average number of units of packed RBCs transfused per month within 12 months v
Časové okno: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Časové okno: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Časové okno: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- D7414R00001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Časový rámec sdílení IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kritéria přístupu pro sdílení IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .